These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15531044)

  • 1. Life-long systemic protection in mice vaccinated with L. major and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes.
    Gabaglia CR; Sercarz EE; Diaz-De-Durana Y; Hitt M; Graham FL; Gauldie J; Braciak TA
    Vaccine; 2004 Nov; 23(2):247-57. PubMed ID: 15531044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice.
    Gabaglia CR; Pedersen B; Hitt M; Burdin N; Sercarz EE; Graham FL; Gauldie J; Braciak TA
    J Immunol; 1999 Jan; 162(2):753-60. PubMed ID: 9916695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages.
    Shimizu Y; Takagi H; Nakayama T; Yamakami K; Tadakuma T; Yokoyama N; Kojima N
    Parasite Immunol; 2007 May; 29(5):229-39. PubMed ID: 17430546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
    Gurunathan S; Prussin C; Sacks DL; Seder RA
    Nat Med; 1998 Dec; 4(12):1409-15. PubMed ID: 9846579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania major MAP kinase 10 is protective against experimental L. major infection.
    Kumari S; Singh S; Saha B; Paliwal PK
    Vaccine; 2011 Nov; 29(48):8783-7. PubMed ID: 21527301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
    Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
    Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania.
    Al-Wabel MA; Tonui WK; Cui L; Martin SK; Titus RG
    Am J Trop Med Hyg; 2007 Dec; 77(6):1060-5. PubMed ID: 18165522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
    Badiee A; Jaafari MR; Khamesipour A
    Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early CD44(hi)CD4+ and CD44(hi)CD8+ T cell numbers and the absence of mannose-rich glycoconjugates determine the protective outcome of anti-leishmanial immunity.
    Kedzierski L; Curtis JM; Kedzierska K
    Parasitology; 2009 Jul; 136(8):833-40. PubMed ID: 19490731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Rafati S; Gholami E; Hassani N; Ghaemimanesh F; Taslimi Y; Taheri T; Soong L
    Vaccine; 2007 May; 25(21):4159-69. PubMed ID: 17395340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK; Titus RG
    Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KM(+), a lectin from Artocarpus integrifolia, induces IL-12 p40 production by macrophages and switches from type 2 to type 1 cell-mediated immunity against Leishmania major antigens, resulting in BALB/c mice resistance to infection.
    Panunto-Castelo A; Souza MA; Roque-Barreira MC; Silva JS
    Glycobiology; 2001 Dec; 11(12):1035-42. PubMed ID: 11805076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental immunization against cutaneous leishmaniasis using Leishmania major subcellular fractions alone or in combination with Phlebotomus duboscqi gut antigens.
    Mbati PA; Anjili CO; Lugalia R; Mwanyumba P; Tonui WK; Robert LL; Githure JI
    East Afr Med J; 1995 Aug; 72(8):519-22. PubMed ID: 7588148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
    Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
    J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.